ULTRAGENYX PHARMACEUTICAL INC (RARE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RARE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RARE | Board member and advisor to various life science companies | 61 | ["Board member and advisor to life science companies", "Independent director with experience in publicly traded biopharmaceutical companies", "Former Executive Vice President of Onyx Pharmaceuticals, Inc.", "Former Chief Financial Officer at Jazz Pharmaceuticals, Inc.", "Former Chief Financial Officer at Perlegen Sciences, Inc.", "Former Chief Financial Officer at ALZA Corporation", "Experience as a manager in the healthcare strategy practice at Andersen Consulting", "B.A. in Accounting from the University of Minnesota", "M.B.A. from the Stanford Graduate School of Business"] | ["Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CRNX | ["Senior Executive Leadership","Regulatory & Compliance","Global Market Access & Commercialization","Corporate Strategy & Business Development","Finance & Capital Markets","Human Capital Management & Succession"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Fust is a board member and advisor to life science companies. Mr. Fust currently serves on the board of directors of Atara Biotherapeutics, Inc., Crinetics Pharmaceuticals, Inc. and Neumora Therapeutics Inc., all of which are publicly traded biopharmaceutical companies. Mr. Fust also previously served on the board of directors of Dermira, Inc., a biopharmaceutical company, from August 2014 to February 2020 and the board of MacroGenics, Inc., a biotechnology company, from March 2014 to May 2020. He retired as Executive Vice President of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 to January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, Inc., a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 to 2002. From 1991 to 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting, a consulting company. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.